© 2003

Fluoropyrimidines in Cancer Therapy

  • Youcef M. Rustum

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-xii
  2. John C. Schmitz, Ashwin Gollerkeri, Xiukun Lin, Jun Liu, Edward Chu
    Pages 67-82
  3. Walter Wolf, Cary A. Presant, Victor Waluch
    Pages 139-152
  4. Roberto Labianca, Gianfranco Pancera, Marinella Mastore, Marina Garassino, Giordano D. Beretta, Paola Poletti et al.
    Pages 175-182
  5. Pascal Piedbois, Marc E. Buyse
    Pages 183-190
  6. Charles Erlichman, Richard M. Goldberg, Daniel J. Sargent
    Pages 191-198
  7. Roy E. Smith, Eleftherios P. Mamounas, Norman Wolmark
    Pages 199-208
  8. Paulo M. Hoff, Everardo D. Saad
    Pages 209-218
  9. Albert Abad, José Luis Manzano
    Pages 229-234
  10. Hedy L. Kindler, Richard L. Schilsky
    Pages 235-247

About this book


Although the action of the standard chemotherapeutic agent for the treatment of advanced colorectal cancer (5-fluorouracil or 5-FU) was improved significantly by combining it with leucovorin (LV), the improved response rate was associated with significant side-effects in approximately thirty percent of patients. In Fluoropyrimidines in Cancer Therapy, leading cancer researchers update and review the mechanisms of action and the therapeutic selectivity and efficacy of 5-FU, with and without LV and its prodrugs, in the treatment of colorectal cancer. Among the combination agents considered are Orzel (UFT/LV), 5-FU/Eniluracil (5-FU/EU), capecitabine (Xeloda), S-1, and a variety of thymidylate synthase inhibitors. The authors discuss the potential advantages and disadvantages of these varied drugs and their mode of administration. Based on the historical results with these agents when used alone, they also present a rationale for their results when used in combination with other agents.
Authoritative and integrative, Fluoropyrimidines in Cancer Therapy summarizes the latest preclinical and clinical experiences using fluoropyrimidines to treat colorectal cancer, delineates the underlying mechanisms and choices for therapy, describes the ongoing search to identify ever more effective and selective agents with novel mechanisms of action, and details the development of new mechanism-based combination therapies.


cell clinical trial liver metastasis pharmacology

Editors and affiliations

  • Youcef M. Rustum
    • 1
  1. 1.Roswell Park Cancer InstituteBuffaloUSA

Bibliographic information

  • Book Title Fluoropyrimidines in Cancer Therapy
  • Editors Youcef M. Rustum
  • Series Title Cancer Drug Discovery and Development
  • DOI
  • Copyright Information Humana Press 2003
  • Publisher Name Humana Press, Totowa, NJ
  • eBook Packages Springer Book Archive
  • Hardcover ISBN 978-0-89603-956-8
  • Softcover ISBN 978-1-61737-274-2
  • eBook ISBN 978-1-59259-337-8
  • Edition Number 1
  • Number of Pages XII, 326
  • Number of Illustrations 0 b/w illustrations, 0 illustrations in colour
  • Topics Oncology
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology